Colon calcium in colon may thus differ by specific tumour molecular subtype.
Experimental studies suggested that calcium may exert anticarcinogenic effects through downregulating cellular proliferation and increasing differentiation and apoptosis. 10 11 The mechanisms behind these effects are not well established, but a promising mediating candidate is the extracellular calcium-sensing receptor (CASR), 12 13 a calcium-binding G protein-coupled receptor that is expressed abundantly in normal colonic epithelium. The CASR has been identified as a key molecule in maintaining systemic calcium homeostasis through actions on the parathyroid gland, kidney, small intestine and bone.
14 Despite a growing body of evidence for the role of calcium in colorectal cancer, no studies to date have examined whether the inverse association between calcium intake and colorectal cancer risk differs according to expression level of CASR in the tumour. We therefore hypothesised that calcium intake was associated with a reduced risk of colorectal carcinomas that overexpress CASR, but not with tumours having no or weak expression of CASR.
To test this hypothesis, we prospectively investigated the association of a long-term calcium intake with colorectal cancer risk according to tumour CASR expression within two large US nationwide cohorts, in which an association has been found between calcium intake and a reduced risk of overall colorectal cancer. 5 15 16 In secondary analysis, the putative difference in the association by CASR expression according to sex, intake sources of calcium, anatomic subsites and tumour molecular characteristics classified by the vitamin D receptor (VDR) expression was also examined.
MeTHODs study population
We conducted this study by using data from the Nurses' Health Study (NHS) and Health Professionals Follow-Up Study (HPFS). Details for the two cohorts have been described elsewhere. 5 17-19 In brief, NHS is a prospective cohort with 121 700 US female registered nurses aged 30-55 years who completed their baseline survey in 1976. 10 HPFS began in 1986 and enrolled 51 529 US male professionals aged 40-75 years at entry. Biennial questionnaires were used to update demographics, lifestyle factors and medical history, and identify newly diagnosed cancers, with follow-up rates over 90% in each cohort. The study protocol was approved by the institutional review boards of the Brigham and Women's Hospital and Harvard TH Chan School of Public Health. A flow chart showing how the study population for analysis was developed is presented in online supplementary figure 1. After excluding participants with a history of cancer (except for non-melanoma skin cancer), polyposis syndrome, ulcerative colitis/Crohn's disease, implausible energy intakes at baseline (<600 or >3500 kcal/day for women, or <800 or >4200 kcal/ day for men) or with no reports of calcium intake, a total of 136 249 participants (88 509 women and 47 740 men) were included in the final analysis.
Assessments of calcium intake and other dietary factors
Details on collections of calcium intake as well as other dietary factors were described previously. 5 15 Briefly, self-reported dietary information was collected at baseline and updated almost every 4 years using a validated, [20] [21] [22] semiquantitative food frequency questionnaire (FFQ) for each cohort. Additionally, we collected information on calcium supplements and multivitamin use in each biennial questionnaire. We used the composition database from the US Department of Agriculture to calculate nutrient intake by multiplying the frequency of each food consumed by the nutrient content per serving of that food, and summing across all foods and beverages. 5 15 We calculated an individual's total calcium intake by summing calcium from dietary sources including fortified foods plus supplements. The calcium from dairy sources alone was calculated by summing the contributions of all dairy products and food items containing dairy products. Calcium from non-dairy sources was calculated by subtracting dairy calcium intake from total dietary calcium intake. 5 15 In the NHS, dairy products contributed to 30%-35% (relatively stable over follow-up), calcium supplement use contributed to about 25% (in early 1990s) to 35% (in 2000s), and multivitamin use contributed to about 3% (in early 1990s) to 8% (in 2000) in total calcium intake; similarly, dairy products contributed to 34%-45%, and multivitamin use contributed to about 3% (in early 1990s) to 8% (in 2000s) in HPFS, as previously reported. 5 The FFQs used in this study have been validated among 127 men from the HPFS 20 and among 173 women from the NHS. 22 The energy-adjusted correlation coefficients of total calcium intake comparing the FFQ and the average of multiple 1-week diet records (four for women and two for men) were 0.61 for men 20 and 0.63 for women. 22 The correlation coefficients for dietary calcium intake were 0.60 for men 20 and 0.70 for women.
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Assessment of covariates
Potential colorectal cancer risk factors including height, adult body weight, physical activity (Metabolic equivalent task scorehours/week), cigarette smoking, sigmoidoscopy/colonoscopy screening, family history of colorectal cancer, aspirin use, and menopausal status and use of menopausal hormones were collected at baseline and updated in biennial follow-up questionnaires. As mentioned above, dietary factors including intakes of alcohol, vitamin D, folate, red meat and processed meat were collected at baseline and updated every 4 years using a validated 131-item (or more) FFQ. 20 
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Ascertainment of colorectal cancer cases
The incident colorectal cancer cases were defined as a primary tumour with International Classification of Diseases-9 codes of 153 and 154. Participants from the two cohorts were asked for written permission to obtain medical records and pathological reports if they reported colorectal cancer on biennial questionnaires. We searched state vital statistics records, the National Death Index, to identify additional unreported cancer deaths. For all deaths attributable to colorectal cancer, we requested permission from next of kin to review medical records. All possible cancer cases were further confirmed through review of medical and pathological records by a study physician who was blinded to exposure data, and information on tumour anatomic location; meanwhile, the stage and histology type of cancer were also retrieved. Outcome data through 1 June 2012 for the NHS and 31 January 2012 for the HPFS were used for the present analysis. During an average follow-up period of 30.4 years in the NHS and 23.2 years in the HPFS, 779 incident colorectal cancer cases with available tumour CASR expression data were documented.
Immunohistochemistry for CAsr expression and VDr expression
As previously described, 23 24 we constructed tissue microarrays (TMA) from colorectal cancer blocks, and conducted immunohistochemistry for CASR and VDR expression. Tumour CASR immunohistochemistry analysis was limited to 779 colorectal Colon cancer cases (461 from the NHS and 318 from the HPFS) with available TMA for the immunohistochemistry (see online supplementary figure 1).
For CASR immunohistochemistry, tissue sections were deparaffinised, rehydrated and heated in a microwave for 15 min in Antigen Retrieval Citra Solution, pH 6 (BioGenex Laboratories, San Ramon, California, USA). Sections were incubated with Dual Endogenous Enzyme Block (Dako, Glostrup, Denmark), followed by the treatment with Protein Block Serum-Free (Dako). Slides were then incubated for 1 hour at room temperature with a rabbit polyclonal anti-CASR antibody (ab137408; Abcam, Cambridge, Massachusetts, USA; dilution, 1:100). The primary antibody was visualised using EnVision+ System-HRP (Dako) with diaminobenzidine and counterstained with haematoxylin. Sections processed with the replacement of primary antibody by Tris-buffered saline were used as a negative control.
Immunohistochemical assessment for CASR was interpreted by a pathologist (YoM) who was unaware of any information concerning the colorectal cancer cases. Tumour CASR expression was scored as 0 (no/minimal staining), 1 (weak staining), 2 (moderately intense staining) and 3 (intense staining) based on the staining intensity in colorectal carcinoma cells according to previously reported criteria. 25 Tumours were classified as CASR-positive (for overexpression) if the score ranged from 2 to 3, while tumours were classified as CASR-negative if the score ranged from 0 to 1 in the present study, to retain statistical power in subgroup analysis of each stratum of CASR subtypes. Despite the lack of a widely accepted, standardised classification scheme for CASR expression in colorectal cancer, the CASR intensity scoring system used in this study was similar to other previous studies. [26] [27] [28] CASR expression levels (four categories, 0, 1, 2, 3) in selected tumours (n=118) were independently examined by a second observer (ZRQ), and the concordance between the two observers was reasonable with a weighted κ of 0.71 (95% CI 0.61 to 0.82). Methods for measuring the VDR expression in tumour have been reported previously. 29 
statistical analysis
Age-adjusted and multivariable-adjusted cohort-specific HRs and 95% CIs for each colorectal cancer subtype (CASR-positive and CASR-negative cancer) were calculated using the duplication method Cox proportional hazards regression model, 30 which was stratified simultaneously by age (in months) and year of questionnaire return (every 2 years since baseline questionnaire), taking into account the finest possible control of confounding for age and secular trends. Person-years of follow-up were calculated from the date of baseline questionnaire return to the date of diagnosis of colorectal cancer, date of death, loss to follow-up or the end of follow-up (1 June 2012 for the NHS and 31 January 2012 for the HPFS), whichever came first. The colorectal cancer cases without tumour CASR data were censored at their diagnosis. We used the energy-adjusted 31 cumulative average intake of total calcium as reported on all available questionnaires up to the start of each 4-year follow-up interval as main exposure 5 to minimise within-person variation and to better reflect longterm intake. Likewise, cumulative average for several covariates including alcohol consumption, total intake of folate, red meat and processed meat was used in the analysis. The adjusted covariates as well as their categorisations in the multivariable models were as indicated in table 2 (see footnotes). When applicable, exposure and covariates (ie, age, body mass index, packyears of smoking, physical activity, alcohol consumption, total intake of vitamin D, red meat and processed meat, history of colorectal cancer in a parent or sibling, history of sigmoidoscopy/ colonoscopy, and regular aspirin use) were modelled as timevarying variables allowing for potential changes over follow-up periods. For variables with missing values (generally 2%-3%), we assigned a separate 'missing' indicator variable and included those participants in the multivariate Cox models. We found no violation of proportionality in testing of the proportional hazard assumption.
To maximise the statistical power, we combined two cohorts to detect the association of calcium intake and risk of colorectal cancer according to CASR expression since we did not observe any significant heterogeneity between cohorts (p heterogeneity for sex=0.43). We examined the statistical significance of the difference in association according to the cancer subtype using the likelihood ratio test that compared the model fit that allows separate associations by different tumour CASR expression status with the model fit that assumed a common effect. The trend tests were conducted using the median of each category of calcium intake as a continuous variable, and p value for trend was calculated using a Wald test.
In secondary analysis, the influence of calcium intake on colorectal cancer risk according to CASR expression stratified by sex was examined. We also considered separately the intake source of calcium and anatomic subsites. Considering that vitamin D plays an important role in calcium absorption and homeostasis, 32 we evaluated the association between calcium intake and risk of colorectal cancer according to joint classification of tumour CASR and VDR expression status. All analyses were performed using the SAS V9.2 software, and a two-sided p value of 0.05 was considered statistically significant.
resulTs baseline characteristics of study participants
Baseline characteristics of participants according to frequency of total calcium intake (<800 mg/day, 800-<1000 mg/day, 1000-<1200 mg/day, ≥1200 mg/day) are shown in table 1. Among the 88 509 eligible women and 47 740 eligible men reporting baseline calcium intake, participants with lower total calcium intake were more likely to be current smokers, consumed more alcohol and tended to have higher intake of red meat, processed meat and fat, but less vitamin D, folate and phosphorous consumption. In NHS, women who consumed less calcium were slightly less physically active compared with those with higher calcium intake. In HPFS, men with lower calcium intake were less likely to have a history of sigmoidoscopy/endoscopy.
As shown in online supplementary table 1, the characteristics of cases with available CASR expression data were similar to those without CASR expression data in terms of mean age (68 years vs 68 years), race (White: 97.4% vs 96.7%), cigarette smoking (current smokers: 22.4% vs 23.9%), mean alcohol consumption (9.3 g/day vs 9.1 g/day), physical activity (19.9 MET-hours/week vs 19.4 MET-hours/week), mean body mass index (26.0 kg/m² vs 26.0 kg/m²), mean total calcium intake (923 mg/day vs 928 mg/day), mean vitamin D intake (379 IU/day vs 373 IU/day) and mean folate intake (468 μg/day vs 462 μg/ day) in the two cohorts.
Calcium intake and colorectal cancer subtype classified by tumour CAsr expression
In the current analysis, we documented 779 (461 cases in NHS and 318 cases in HPFS) incident colorectal cancer cases with available tissue for analysis of CASR expression. Among these 779 tumours, 186 (23.9%) had moderate CASR expression, 443 In testing our primary hypothesis that the inverse association between calcium intake and colorectal cancer risk might differ by CASR expression, we found that the inverse association with high total calcium intake appeared to be restricted to CASR-positive tumours (p trend =0.003, comparing ≥1200 vs <600 mg/day: multivariable HR=0.67, 95% CI 0. 51 In secondary analysis, the differential associations between calcium intake and cancer risk according to CASR expression status were consistent across tumour anatomic subsite (online supplementary table 2), although the heterogeneity test did not reach statistical significance. Furthermore, the differential associations appeared slightly stronger in VDR-positive tumours but not in VDR-negative cancers (online supplementary table 3).
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DIsCussIOn
To our knowledge, this is the first molecular pathological epidemiology (MPE) study to test the hypothesis that the inverse association between calcium intake and the risk of colorectal cancer might differ by tumour CASR expression status. The hypothesis was based on the combination of two different lines of evidence. First, high calcium intake was associated with a lower risk of colorectal cancer in the majority of the epidemiological studies. [3] [4] [5] [6] [7] Second, the CASR might have tumour suppressive roles in the colon, [33] [34] [35] and extracellular ionised calcium is the primary agonist of CASR. 36 37 This hypothesis-driven study found that high calcium intake appeared to be associated with the lower risk of CASR-positive colorectal adenocarcinomas, but not with the CASR-negative tumours.
The observed differential association between calcium and colorectal cancer by CASR expression status has biological support. Calcium may activate certain signalling pathways that are involved in regulating the balance between proliferation, differentiation and apoptosis of colonic epithelial cells via CASR through the promotion of E-cadherin expression, the suppression of beta-catenin/T cell factor activation, 35 36 as well as the activation of p38 mitogen-activated protein kinase cascade. 36 38 39 Additionally, previous studies indicated that CASR could mediate the proliferative effects of low intestinal calcium concentration. 34 40 The CASR is expressed abundantly in normal colonic epithelium and progressively downregulated or lost during colorectal carcinogenesis. 41 42 Although the underlying mechanisms leading to this loss of expression are not well understood, methylation of CASR promoter 2, loss of histone acetylation and aberrant expression of microRNAs (eg, overexpression of miR-135b and miR-146b) 41 43 may partly explain this silencing expression of the CASR in the colorectal cancer. In addition, loss of CASR expression appeared not to be an early event in tumourigenesis; indeed it could be correlated with late stage, poorly differentiated, chemoresistant cancers. 13 Therefore, the possible beneficial effects of calcium in colorectal carcinogenesis may be impaired or lost 10 13 due to the decreased CASR expressions in the tumours. 44 45 Although most epidemiological studies have suggested a lower risk of colorectal cancer and adenoma associated with higher calcium intake, whether this association represents causality or confounding remains unsettled. A large randomised controlled trial involving 36 282 postmenopausal women found no significant benefit of 1000 mg/day of elemental calcium plus 400 IU of vitamin D3 on colorectal cancer risk during an average of 7 years of follow-up. 46 However, several design limitations in this trial 46 could have partly explained the negative findings, including the generally high calcium intake in the study population, relatively poor compliance and short duration. Another randomised controlled trial examined the association of supplementations with 1200 mg/day of calcium carbonate and 1000 IU/day vitamin D with the risk of colorectal adenomas among 2259 patients who underwent at least one colorectal adenoma resection before enrolment, with follow-up duration of 3-5 years, and yielded a null association. 47 However, unadjusted confounders, 48 short surveillance periods 48 49 and the narrow scope of study population 49 within this trail may have influenced its conclusion. The assessment of the association of calcium with colorectal cancer subtypes characterised by molecular pathological features may improve the understanding for the potential causal relationship between calcium and colorectal cancer, and give hints about the molecular mechanisms by which calcium exerts its chemopreventive functions in colorectal carcinogenesis. The observed subtype-specific difference in the association between CASR-positive and CASR-negative colorectal adenocarcinomas provides evidence that calcium may causally decrease colorectal cancer risk.
Despite results from human genetic epidemiological studies showing significant associations between single nucleotide polymorphisms (SNPs) in CASR and colorectal cancer risk, [50] [51] [52] [53] [54] no interactions have been noted to date for any of the SNPs with the level of dietary calcium intake among few existing studies. [53] [54] [55] [56] Given the limited number of studies, more studies are warranted to examine gene-environment (ie, CASR gene-calcium) interaction and evaluate SNPs in CASR and tumour expression of CASR.
Our findings of the potentially differential associations were robust. The stronger inverse association for the CASR-positive but not CASR-negative tumours appeared not dependent on sources of calcium intake and generally consistent across the anatomic subsites. However, we previously found that in our cohorts higher calcium intake appeared only associated with lower risk of distal colon cancer. 5 15 Whether differential proportions of CASR-positive and CASR-negative cancers across subsites contribute to apparently stronger associations for calcium with distal colon cancer requires larger study sizes.
Interestingly, although not statistically significant, we found that the differential association of calcium and colorectal cancer by CASR expression status appeared slightly stronger in VDR-positive tumours than in VDR-negative tumours, implying potential cross-talk between the CASR and the vitamin D system in the prevention of colorectal cancer. According to a review, 57 the active vitamin D metabolite, 1,25-dihydroxyvitamin D 3 , bound to VDR can induce translation of the CASR; on the other hand, the amount and activity of the CASR might affect 1,25-dihydroxyvitamin D 3 signalling. The complexity of the cross-talk between the CASR and the vitamin D system appeared Colon Table 2 Duplication method Cox proportional cause-specific hazards regression for competing risks data was used to compute HRs and 95% CIs. All analyses were stratified by age (in month), year of questionnaire return and sex. *The likelihood ratio test was used to test for the heterogeneity of the association between total calcium intake and colorectal cancer risk by CASR expression. †Multivariable HRs were adjusted for age (in month), race (Caucasian vs non-Caucasian), adult body mass index (<25, 25-<27.5, 27.5-<30 or ≥30 kg/m 2 ), smoking (0, 1-10, or >10 pack-years), history of colorectal cancer in a parent or sibling (yes or no), history of sigmoidoscopy/colonoscopy (yes or no), physical activity (<3, 3-<27, ≥27 MET-hours/week), regular aspirin use (yes, no), alcohol consumption (0-<5, 5-<15, or ≥15 g/day), and total intake of vitamin D, folate, red meat and processed meat (all in tertiles). ‡Linear trend test using the median intake of each category. CASR, calcium-sensing receptor; MET: metabolic equivalent task score; HPFS, Health Professionals Follow-Up Study; NHS, Nurses' Health Study. Table 3 Intake of dietary calcium, dairy calcium and calcium supplement and risk of colorectal cancer according to tumour CASR expression in the Nurses' Health Study Duplication method Cox proportional cause-specific hazards regression for competing risks data was used to compute HRs and 95% CIs. All analyses were stratified by age (in month), year of questionnaire return and sex. *The likelihood ratio test was used to test for the heterogeneity of the association between calcium intake and colorectal cancer risk by expression of CASR. †Multivariable HRs were adjusted for age (in month), race (Caucasian vs non-Caucasian), adult body mass index (<25, 25-<27.5, 27.5-<30 or ≥30 kg/m 2 ), smoking (0, 1-10 or >10 pack-years), history of colorectal cancer in a parent or sibling (yes or no), history of sigmoidoscopy/colonoscopy (yes or no), physical activity (<3, 3-<27, ≥27 MET-hours/week), regular aspirin use (yes or no), alcohol consumption (0-<5, 5-<15 or ≥15 g/day), and total intake of vitamin D, folate, red meat and processed meat (all in tertiles). ‡Linear trend test using the median intake of each category. CASR, calcium-sensing receptor; MET: metabolic equivalent task score.
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to go beyond affecting expression mutually 57 and needs further investigations.
The strengths of the current study include its prospective cohort design with large sample size, long follow-up periods for validated colorectal cancer outcomes and high follow-up rate of over 90% in each cohort. In addition, taking into account the repeated measures of calcium and other covariates during the follow-up periods may strengthen the association. Lastly, we used the MPE approach, 9 58 which enabled us to investigate aetiological heterogeneity according to tumour molecular features, and provide evidence in support of differential association of calcium intake and colorectal cancer risk.
However, our study has several limitations. First, residual confounding cannot be totally ruled out, although our detailed data resources enabled us to adjust for a variety of potential confounders including known and suspected risk factors for colorectal cancer. Nonetheless, age-adjusted results were similar to multivariable-adjusted results. Second, although the parent cohorts are large overall, we had limited number of cancer cases with available tumour CASR expression; therefore, future MPE studies with more available tumour tissues are needed to replicate our findings. Third, the exclusion of cancer cases without tissue specimen may introduce potential selection bias. However, cases with tumour CASR data were comparable with all eligible cases with regard to a number of demographic, diet and lifestyle factors. Fourth, our findings were likely to be influenced by the potential misclassification of CASR expression status. This misclassification could be non-differential and would bias the results towards the null (ie, non-significant difference in the association by CASR expression status) in our cohorts. However, a blinded and independent assessment of CASR expression was performed, and we confirmed a substantial interobserver agreement between the two observers. Lastly, our study population consisted mainly of Caucasian US health professionals and the results may not be generalisable to other ethnic groups. Nonetheless, the association between calcium intake and lower risk of colorectal cancer and adenoma has been observed with little heterogeneity across diverse populations. 6 59 In summary, we observed that calcium intake is inversely associated with the risk of CASR-positive, but not with CASR-negative, colorectal cancer. Our finding supported the hypothesis that the CASR may partially mediate the anticarcinogenic effect of calcium in the colon, and highlighted the potential use of CASR as a molecular marker for colorectal cancer. Future studies with more available tumour specimens are needed to confirm these findings and better understand the related mechanisms.
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